Dong Wen

1 clinical trials · Sponsor

Record	Firm	Date
Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma (NCT07047001)	Dong Wen	2025-04-24

Every clearance here is in the API, with alerts when new ones post.